The bill line reads like something from a hospital in 2040: invasive brain-computer interface implantation fee, RMB 6,552 per procedure.
On November 26, 2025, a 31-year-old man with a spinal cord injury was wheeled into an operating theatre at Tongji Hospital in Wuhan. Surgeons placed a 64-channel flexible electrode array at the brain regions that control and sense his hand, using a device built by Wuhan Zhonghua (衷华脑机). The operation went as planned. He was stable afterwards.
What made the case unusual had nothing to do with the surgery. It was the first brain-computer interface procedure in China carried out against a government-set price list. A number existed, published in advance, for something that had never been billed before.
The patient did not pay it. Because brain-computer interface (脑机接口) treatment in China still sits in clinical research rather than routine care, the cost was carried by research funding rather than billed to him. That detail is the whole story in miniature: China has built the billing infrastructure for a therapy that has not yet arrived at the cashier.
Three Line Items, One Province
The architecture came in March 2025, when the National Healthcare Security Administration (国家医保局) issued a trial guideline on price items for neurological medical services. Buried among routine entries were three new ones created specifically for brain interfaces:
- Invasive BCI implantation fee — surgical planning, incision or puncture, electrode placement, signal testing and fixation.
- Invasive BCI removal fee — the same work plus device extraction and wound repair.
- Non-invasive BCI adaptation fee — electrode placement, signal capture, algorithm tuning, data analysis and system optimisation.
The guideline did not set national prices. It created the categories and left the numbers to provinces. Hubei moved first, publishing RMB 6,552 (≈US$910 / HK$7,100) for implantation, RMB 3,139 (≈US$436 / HK$3,400) for removal, and RMB 966 (≈US$134 / HK$1,050) for non-invasive fitting.
By May 2026 the national picture had converged: guided prices for invasive implantation clustered between RMB 6,000 and 6,600 (≈US$833–917), with non-invasive adaptation at roughly RMB 960 (≈US$133). The same health-insurance authority noted that about 180 new-technology price items had been added across the system in three years — proton therapy, surgical robotics, tissue printing — with brain interfaces among the earliest and most deliberate.
Why a Price List Beats a Subsidy
A grant funds one surgery. A price item funds an industry, because it changes what four different parties can do on the same day.
For hospitals, a billable code turns an experiment into a service line. A department can budget staff, book theatre time and argue for equipment without writing a research proposal each time. For device makers, it converts "we hope someone pays" into a revenue model an investor can discount. For provincial insurers, it creates a reference point for future negotiation. For patients, it replaces an opaque lump sum with a receipt.
Note what the price actually buys: surgeon time and operating theatre work. It does not include the implant. It does not include the weeks of rehabilitation that decide whether a decoded signal becomes a usable hand movement. It does not include the programming sessions that will continue for years, nor the imaging, nor the complications that may need a second operation.
By international standards the surgical fee is startlingly low. A retinal implant sold in the United States in the 2010s carried a total cost of surgery and maintenance reported at roughly US$500,000 (≈HK$3.9 million). China's number is roughly one five-hundred-and-fiftieth of that — and the gap is precisely the political point. The pricing authority is not trying to make brain interfaces lucrative. It is trying to make them ordinary.
The Cost Nobody Has Priced Yet
Three gaps remain, and each one is bigger than the last.
The device. No public price exists for the implant itself. Early commercial units are effectively bundled into research programmes or hospital procurement, which means the true cost per patient is still unknown outside the negotiating room.
The labour after surgery. A brain interface is not a one-off purchase. Decoding drifts as scar tissue forms and electrode contacts shift; users need re-calibration, and therapists need to teach the brain a new mapping between intention and movement. In China's rehabilitation system, that labour is billed through separate therapy items, at rates that vary widely by province.
The evidence base. Implanted interfaces remain Class III high-risk active devices. Regulators want multi-year follow-up on safety, and national basic medical insurance (基本医保) coverage generally follows that evidence, not the price list. A published price is a door. It is not yet an open one.
Beyond those three, a fourth gap is rarely discussed: the price list assumes a straightforward transaction, but brain surgery for paralysis is rarely straightforward. Infection, electrode migration, and the plain fact that some patients gain less function than hoped all sit outside the fee schedule.
Honest limitations
This article relies on the pricing guideline as published by the National Healthcare Security Administration, the State Council's news portal, and Chinese state and professional media reporting on the Hubei schedule and the Wuhan operation. I did not review hospital invoices, and the Hubei figures apply to that province — other provinces set their own levels within a band, so a reader in Guangdong or Sichuan should not assume identical numbers.
The clinical outcome of the Wuhan case has not been published as peer-reviewed data, and one operation is not evidence that the procedure works at scale. The comparison to the US retinal implant is a cost-order comparison, not a like-for-like clinical one: different organ, different era, different regulatory system. And the RMB-to-dollar conversions here use an approximate rate of 7.2, not a settlement rate.
I also cannot tell you what the implant itself costs, because nobody has published it.
What readers can do now
- If you or a family member is considering an implanted interface in China, ask the hospital three questions in writing: is this clinical research or a marketed device, who pays if a complication needs a second surgery, and what the five-year support arrangement is. The published surgical fee answers none of them.
- If you work in health economics or hospital administration, treat the three new items as a natural experiment. Provinces that set different prices for identical procedures will generate the first real data on how price affects adoption of neurotechnology.
- If you are an investor, do not read RMB 6,552 as a revenue figure. Read it as a signal that the reimbursement pathway is being built ahead of the products, which historically favours whoever gets a registration certificate first.
A price tag is a strange milestone. It tells you nothing about whether the technology works, and everything about whether the system has decided it intends to use it.
